FrederickCostonBeddingfieldMDPhD

Dermatology • Los Angeles, CA

Assistant Clinical Professor, Dermatology, UCLA School of Medicine

Join to view full profile

Dr. Beddingfield is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Beddingfield's full profile

Already have an account?

Office
200 Medical Plz
# 450
Los Angeles, CA 90095
Phone+1 310-825-0631

Fax+1 310-794-7005

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Dermatology, 1998 - 2001
Los Angeles County-Harbor-UCLA Medical CenterResidency, Emergency Medicine, 1991 - 1995
University of North Carolina at Chapel Hill School of MedicineClass of 1991

Certifications & Licensure

CA State Medical License 1992 - 2026
CO State Medical License 1995 - 1999
American Board of Dermatology Dermatology

Awards, Honors, & Recognition

Fellow (FASDS) American Society for Dermatologic Surgery

Clinical Trials

Phase 2 Study of Deoxycholic Acid Injection (ATX-101) for the Reduction of Submental Fat Start of enrollment: 2008 Apr 01
Completed
Phase 2
Dose-Escalation Safety and Pharmacokinetic Study of ATX-101 Start of enrollment: 2008 Jan 01
Completed
Phase 1
Patient Experience Study of Deoxycholic Acid Injection Start of enrollment: 2013 Dec 01
Completed
Phase 3
Safety Study of ATX-101 (Deoxycholic Acid) in Subjects With Mild or Extreme Fullness of Submental Fat Start of enrollment: 2014 Jan 01
Completed
Phase 3
Safety Study of Deoxycholic Acid for the Reduction of Localized Subcutaneous Fat in the Submental Area in Subjects 65 to 75 Years of Age Start of enrollment: 2014 Apr 01
Completed
Phase 3
Long Term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101 Start of enrollment: 2009 Feb 01
Completed
Phase 2
Long-term Follow-up Study on Safety and Maintenance of Efficacy of ATX-101 Start of enrollment: 2013 Dec 01
Completed
Phase 3
Join now to see all

Publications & Presentations

PubMed

31 citations
Long-term safety and efficacy of bimatoprost solution 0·03% application to the eyelid margin for the treatment of idiopathic and chemotherapy-induced eyelash hypotrich...
D.A. Glaser, Parwez Hossain, W. Perkins, T.W. Griffiths, G. Ahluwalia
The British Journal of Dermatology. 2015-05-01
53 citations
Eyelash growth in subjects treated with bimatoprost: a multicenter, randomized, double-masked, vehicle-controlled, parallel-group study.
Stacy Smith, Steven Fagien, Scott M. Whitcup, Fred Ledon, Christine Somogyi
Journal of the American Academy of Dermatology. 2012-05-01
13 citations
Patient-reported outcomes of bimatoprost for eyelash growth: results from a randomized, double-masked, vehicle-controlled, parallel-group study.
Steven Fagien, John G. Walt, Jean Carruthers, Sue Ellen Cox, David Wirta
Aesthetic Surgery Journal. 2013-08-01

Lectures

Myth Busters: A Critical Evaluation of the Evidence Behind Common Cosmetic Recommendations
American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/3/2019

Press Mentions

Kira Pharmaceuticals Announces First Cohort of Patients Dosed in Phase 2 Study of KP104 in Paroxysmal Nocturnal Hemoglobinuria (PNH)November 30th, 2022
Kira Pharmaceuticals Receives FDA Orphan Drug Designation for KP104, a Bifunctional Antibody Fusion Protein, for the Treatment of Paroxysmal Nocturnal HemoglobinuriaJuly 28th, 2022
Kira Pharmaceuticals Expands Executive Leadership Team with Chief Business Officer, Chief Medical Officer and Chief Commercial Officer, ChinaFebruary 23rd, 2021
Join now to see all

Professional Memberships

American Society for Dermatologic Surgery - ASDS
Fellow